CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04901195
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-23T00:05:38.476763+00:00
Published At: 2026-06-22T00:00:00+00:00
Record Updated At: 2026-06-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hidradenitis Suppurativa"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-22"
protocolSection.identificationModule.nctId: "NCT04901195"
protocolSection.identificationModule.officialTitle: "A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.